{"url_path":"/sec/ltrn/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023758-index.html","accession_number":"0001493152-26-023758","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023758-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":98,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Exhibit\nDescription**\n\n \n \n \n\n99.1\n \n[Press Release dated May 15, 2026 announcing financial results for first quarter ended March 31, 2026.](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nLantern\nPharma Inc.,\n\n \nA\nDelaware Corporation\n\n \n \n\nDated:\nMay 15, 2026\nBy:\n*/s/\nDavid R. Margrave*\n\n \n \nDavid\nR. Margrave, Chief Financial Officer\n\n \n\n3\n\n \n\n** **"}